Ondine Biomedical Inc. (AIM:OBI)

Market Cap	41.09M -15.7%
Revenue (ttm)	1.18M +34.8%
Net Income	-12.79M
EPS	-0.03
Shares Out	444.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,800
Average Volume	214,253
Open	9.50
Previous Close	9.25
Day's Range	9.00 - 9.50
52-Week Range	7.50 - 18.50
Beta	0.24
RSI	70.75
Earnings Date	May 12, 2026

About Ondine Biomedical

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 18
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: OBI

Financial Performance

In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.

Financial numbers in CAD